PubMed Health⌕ Search

PubMed · 12075969

Time of flight diffraction imaging for double-probe technique.

Abstract

Due to rapid progress in microelectronics and computer technologies, the system evolving from analog to digital, and a programmable and flexible synthetic aperture focusing technique (SAFT) for the single-probe pulse-echo imaging technique of ultrasonic nondestructive testing (NDT) becomes feasible. The double-probe reflection technique usually is used to detect the nonhorizontal flaws in the ultrasonic NDT. Because there is an offset between the transmitter and receiver, the position and size of the flaw cannot be directly read from the image. Therefore, a digital signal processing (DSP) imaging method is proposed to process the ultrasonic image obtained by double-probe reflection technique. In the imaging, the signal is redistributed on an ellipsoid with the transmitter and receiver positions as focuses, and the traveltime sum for the echo from the ellipsoid to the focuses as the traveltime of signal. After redistributing all the signals, the useful signals can be constructively added in some point in which the reflected point is; otherwise, the signals will be destructively added. Therefore, the image resolution of the flaw can be improved and the position and size of the flaw can be estimated directly from the processed image. Based on the experimental results, the steep flaw (45 degrees) cannot be detected by the pulse echo technique but can be detected by the double-probe method, and the double-probe B-scan image of 30 degrees tilted crack is clearer than the pulse echo B-scan image. However, the flaw image departs from its true position greatly. After processing, the steep flaw image can be moved to its true position. When the flaws are not greater than the probe largely, the sizes of the flaws are difficult to be discriminated in both pulse echo and double-probe B-scan images. In the processed double-probe B-scan image, the size of the flaws can be estimated successfully, and the images of the flaws are close to their true shape.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Young-Fo Chang, Cheng-I Hsieh. 2002. Time of flight diffraction imaging for double-probe technique.. https://doi.org/10.1109/tuffc.2002.1009335

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗